We propose that the lack of pre-clinical models that recapitulate diverse genetics as well as the assumption that findings in KRASG12D/mutant p53 tumours from KPC mice are generalisable to other contexts contribute to the high failure rate of translating pre-clinical observations to the clinic. The gene discussed is TP53; the disease is neoplasm.